scholarly journals The pursuit of mechanism of action: uncovering drug complexity in TB drug discovery

2021 ◽  
Author(s):  
Tianao Yuan ◽  
Joshua M. Werman ◽  
Nicole S. Sampson

The tools that have been successfully employed to understand the mechanism of action of TB therapeutics are discussed to offer insights into the future of mechanistic assessment in M. tuberculosis.

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1015
Author(s):  
Utsa Bhaduri ◽  
Giuseppe Merla

Ubiquitination is a post-translational modification that has pivotal roles in protein degradation and diversified cellular processes, and for more than two decades it has been a subject of interest in the biotech or biopharmaceutical industry. Tripartite motif (TRIM) family proteins are known to have proven E3 ubiquitin ligase activities and are involved in a multitude of cellular and physiological events and pathophysiological conditions ranging from cancers to rare genetic disorders. Although in recent years many kinds of E3 ubiquitin ligases have emerged as the preferred choices of big pharma and biotech startups in the context of protein degradation and disease biology, from a surface overview it appears that TRIM E3 ubiquitin ligases are not very well recognized yet in the realm of drug discovery. This article will review some of the blockbuster scientific discoveries and technological innovations from the world of ubiquitination and E3 ubiquitin ligases that have impacted the biopharma community, from biotech colossuses to startups, and will attempt to evaluate the future of TRIM family proteins in the province of E3 ubiquitin ligase-based drug discovery.


2011 ◽  
pp. 235-251
Author(s):  
Devan Marar ◽  
Shobha H. Ganji ◽  
Vaijinath S. Kamanna ◽  
Moti L. Kashyap

MedChemComm ◽  
2014 ◽  
Vol 5 (3) ◽  
pp. 386-396 ◽  
Author(s):  
Georgios Drakakis ◽  
Adam E. Hendry ◽  
Kimberley Hanson ◽  
Suzanne C. Brewerton ◽  
Michael J. Bodkin ◽  
...  

Given the increasing utilization of phenotypic screens in drug discovery also the subsequent mechanism-of-action analysis gains increased attention.


2012 ◽  
Vol 17 (8) ◽  
pp. 1005-1017 ◽  
Author(s):  
Danli L. Towne ◽  
Emily E. Nicholl ◽  
Kenneth M. Comess ◽  
Scott C. Galasinski ◽  
Philip J. Hajduk ◽  
...  

Efficient elucidation of the biological mechanism of action of novel compounds remains a major bottleneck in the drug discovery process. To address this need in the area of oncology, we report the development of a multiparametric high-content screening assay panel at the level of single cells to dramatically accelerate understanding the mechanism of action of cell growth–inhibiting compounds on a large scale. Our approach is based on measuring 10 established end points associated with mitochondrial apoptosis, cell cycle disruption, DNA damage, and cellular morphological changes in the same experiment, across three multiparametric assays. The data from all of the measurements taken together are expected to help increase our current understanding of target protein functions, constrain the list of possible targets for compounds identified using phenotypic screens, and identify off-target effects. We have also developed novel data visualization and phenotypic classification approaches for detailed interpretation of individual compound effects and navigation of large collections of multiparametric cellular responses. We expect this general approach to be valuable for drug discovery across multiple therapeutic areas.


2018 ◽  
pp. 399-404
Author(s):  
S. Nassir Ghaemi

Newer and better medications are obtained as part of the drug discovery process, which occurs mainly in the pharmaceutical industry. This process is hampered by excessive attention to marketing demands, as opposed to scientific exploration. It also is impaired by the psychiatric profession’s mistaken ideologies, whether psychoanalytic orthodoxy in the past or DSM beliefs of the present. Wrong clinical phenotypes impair finding new pharmacological mechanisms and targeting them well to the write clinical indications. Perhaps as a consequence, no treatments have been developed in the last few decades, since DSM-III, that are more effective than prior agents. Progress for the future in drug discovery will require not just better neurobiological work, but also a new approach to clinical diagnoses in psychiatry.


2017 ◽  
Vol 53 (37) ◽  
pp. 5167-5170 ◽  
Author(s):  
Lindsay E. Evans ◽  
Keith Jones ◽  
Matthew D. Cheeseman

A non-nucleotide FP-probe was designed to study the mechanism of action and druggability of the secondary HSP70/BAG1 complex.


2010 ◽  
Vol 5 (2) ◽  
pp. 159-161 ◽  
Author(s):  
Teresa V. Bowman ◽  
Leonard I. Zon
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document